May 14, 2020 / 12:30 PM / 21 days ago

BRIEF-Seattle Genetics Says Adcetris Receives European Commission Approval For Treatment Of Adult Patients With Previously Untreated Systemic Anaplastic Large Cell Lymphoma

May 14 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES ADCETRIS® (BRENTUXIMAB VEDOTIN) RECEIVES EUROPEAN COMMISSION APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below